Andrew Balber

Andrew E. Balber is a Senior Scientific Advisor to the Robertson Clinical & Translational Cell Therapy Program at Duke University. Most of his current efforts there are directed at developing cord blood derived cell products for repair of neural injuries and moving these products into the clinic. Dr. Balber has been working in early product development in various commercial and academic contexts 1983. Among other positions, he was a Founder, and for ten years served as the Chief Scientific Officer, of Aldagen, Inc. Dr. Balber also provides consulting services in cell therapy.